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ABSTRACT. Laponite clay is able to retain dexamethasone by simple physisorption, 
presumably accomplished by hydrogen bonding formation and/or complexation with sodium 
counterions, as shown by solid state NMR. The physisorption can be somehow modulated by 
changing the solvent in the adsorption process. This simple system is able to deliver 
dexamethasone in a controlled manner to solutions used as models for vitreous humor. The 
proved biocompatibility of laponite as well as its transparency in the gel state, together with 
the simplicity of the preparation method, make this system suitable for future in vivo tests of 
ophthalmic treatment. 
21. Introduction 
Among the treatments for posterior segment ocular diseases, intravitreal injection is 
considered an effective approach, as it delivers the therapeutic agent directly into the eye 
[1,2]. In spite of some advantages with respect to systemic administration, such as lower side 
effects, intravitreal injection presents some potential risks associated to the need for repeated 
injections [3]. In the last years, alternative drug delivery systems are being developed to 
overcome this kind of limitations by reducing the frequency of injections, and hence the 
potential complications [4-6]. For example, dexamethasone (DEX) has been released from 
biodegradable subconjunctival implants of a poly(ortho ester) [7], from intravitreal implants 
of poly((-caprolactone) [8], or poly(lactic-co-glycolic acid) [9]. The degradation of the 
polymeric matrix produces the slow release of DEX, but this methodology requires a surgical 
intervention to implant the material [8,10]. 
Very recently an intravitreal injectable implant has been described using DEX encapsulated 
into a thermogel matrix of poly(lactic acid-co-glycolic acid)poly(ethylene glycol)
poly(lactic acid-co-glycolic acid) triblock copolymer, able to lengthen the ocular retention 
time of DEX from several hours to more than one week [11]. In this case the matrix was 
prepared by copolymerization of lactic acid and glycolic acid, using poly(ethylene glycol) as 
initiator. Other hydrogels based on poly(ethylene glycol) and poly(valerolactone) [12] or
hyaluronic acid [13,14] have been also used for DEX release, but not in ophthalmic 
applications. 
Clay minerals play different roles in health care formulations [15,16], mainly for topical and 
gastrointestinal diseases, but only recently they have been envisaged as drug delivery 
modulators [17-19]. Natural clays show a certain degree of variability in their properties, 
such as chemical composition, particle size, and color. Hence, it is very difficult to envisage 
their use in intravitreal applications, and only in one case they have been used as components 
of polyurethane composites for implants releasing dexamethasone acetate upon degradation 
of the polymer [20]. However, synthetic clays are prepared with reproducible composition 
and textural properties. As an example, laponite (LAP) is a white synthetic smectite clay, a 
layered hydrous magnesium silicate with an empirical formula of 
Na0.7[(Si8Mg5.5Li0.3)O20(OH)4] that forms transparent colloidal dispersions in water [21]. As 
sodium cations are exchangeable, this property has been used to immobilize cationic drugs, 
usually molecules with protonated amino groups, that can be released in aqueous saline 
3solutions. This is the case of itraconazole [22] (anti-fungal drug), donepezil [23] (Alzheimers 
disease), tetracycline [24] (antimicrobial agent), and doxorubicin [25] (antitumoral). In vivo
studies with the doxorubicin-laponite system have shown a high antitumor efficacy of the 
system with very low toxicity [26], whereas the laponite disks can be modified with folic acid 
for targeted drug delivery [27].
Here, we describe the first report of immobilization a non-ionic drug, dexamethasone, on 
laponite clay, the nature of the drug-clay interaction and the in vitro behavior of the material 
in controlled delivery. 
2. Materials and methods 
2.1. Materials 
Dexamethasone (DEX) was from Aldrich. Laponite (LAP) was from Rockwood Additives. 
Ethanol, acetone and acetonitrile were HPLC grade from Scharlab. CD2Cl2, CD3OD, acetone-
d6 and dmso-d6 were from Aldrich. Sodium hyaluronate 3% solution (Healon EndoCoat 
OVD) was from Abbott Medical Optics. Saline solution (9 mg/mL NaCl) was from Fresnius 
Kabi España. 
2.2. Preparation and characterization of DEX/LAP 
The required amount of DEX (20, 10 or 5 mg) was dissolved in ethanol or acetone (10 mL) 
and LAP (100 mg) was added to this solution. The slurry was stirred at room temperature for 
1 h and then the solvent was removed in a rotary evaporator. In that way, the whole amount 
of DEX was deposited on the laponite support. The solid was dried at room temperature 
overnight under vacuum over P2O5. 
DEX contents were assessed (less than 0.5% error) by carbon analysis of the dried powders in 
a Perkin-Elmer EA-2400 Series II elemental analyzer. Extraction of the samples with 
acetonitrile for 1 h led to the complete release of DEX to solution, as determined by HPLC 
(see below). FT-IR spectra (250 scans) of KBr pellets were registered using a Thermo-
Nicolet Nexus 5700 spectrometer in the range from 4000 to 600 cm-1 at a resolution of 4 
cm1. 13C CP-MAS NMR (cross-polarization magic angle spinning nuclear magnetic 
resonance) spectra were recorded in a Bruker Avance III WB400 spectrometer with 4 mm 
zirconia rotors spun at magic angle in N2 at 10 kHz. Spectra (1000-25000 scans depending on 
4the sample) were measured using a 1H /2 pulse length of 3 s, with a contact time (ramp) of 
3 ms, spinal64 proton decoupling sequence of 5.3 s pulse length and recycle delay of 7 s. 
Dipolar dephasing (DD) spectra were recorded under the same conditions with a dephasing 
delay of 50 s and a refocusing 13C  pulse of 8 s. Solution NMR spectra were recorded in a 
Bruker Avance 400 spectrometer. Step scanned (1s/step) X-ray diffraction patterns were 
collected in the Servicio de Difracción de Rayos X y Análisis por Fluorescencia del Servicio 
General de Apoyo a la Investigación de la Universidad de Zaragoza at room temperature 
from 3º in 2 up to 35º, using a D-Max 2500 Rigaku system with a rotating anode. CuK
radiation with a wavelength of 1.54 Å at 40 kV and 80 mA was used. 
2.3. In vitro DEX release studies 
Release was studied in two extraction media, saline solution and a model of vitreous humor 
made up of 0.5% sodium hyaluronate in saline solution. The release tests were performed by 
dispersing DEX/LAP (20 mg) in the extraction medium (2 mL of saline or 2 g of the vitreous 
model) under stirring at 120 rpm at room temperature. After 24 h the dispersion was 
centrifuged at 14000 rpm for 20 min. The liquid phase was removed and analyzed, while the 
solid was re-dispersed in fresh extraction medium for a new cycle. 
The analysis of DEX was carried out by HPLC in a Waters 2695 system equipped with a 
Phenomenex Kinetex C18 column (75 mm × 4.6 mm × 2.6 m) coupled to a Waters 2995 
PDA detector. The mobile phase was acetonitrile/water (35:65 v/v) pumped at a flow rate of 
0.2 mL/min at 35ºC. Detection at 250 nm was used. The amount of DEX was calculated by a 
seven point calibration curve against 6--methylprednisolone (internal standard). Aliquots of 
the extraction medium (200 L) were mixed with acetonitrile (2 mL) and 100 L of a 
solution of standard (20 ppm in acetonitrile). The solution was then vortexed for 1 min and 
sonicated for 5 min to ensure the complete mixing, and finally centrifuged at 3000 rpm for 5 
min. The supernatant was collected and evaporated under vacuum, then redissolved in 200 
L of acetonitrile, filtered through a 0.22 m PTFE syringe filter and analyzed by HPLC. 
The presence of laponite in the supernatant was not detected in any case. 
53. Results and discussion 
3.1. Characterization of adsorbed DEX 
In contrast with other drugs immobilized on LAP [22-25], DEX is not cationic and it cannot 
interact with the solid surface through electrostatic forces. Thus, it was deposited on LAP by 
suspending the clay in an ethanol solution of the drug, with three different DEX/LAP weight 
ratios, 1:20, 1:10 and 1:5, labeled as low, medium and high, as the optimal situation would be 
the use of the minimum amount of support for intravitreal injections. The solids were 
obtained by simply evaporating the solvent under reduced pressure. 
As the immobilization of DEX on LAP cannot be due to electrostatic interactions through the 
exchange of sodium cations, the distribution of DEX on the surface is not easily predictable. 
X-ray diffraction was used to determine whether the dexamethasone molecules were able to 
enter the interlayer space of laponite, leading to an increase in the basal spacing of the clay. 
As can be seen in Figure 1A, the powder patterns are poorly oriented, and the 001 line is not 
clearly defined and it appears as a shoulder. In DEX(high)/LAP, the sharp diffraction lines 
corresponding to pure orthorhombic DEX (JCPDS database) are observable, indicating the 
presence of DEX crystallites. This pattern is different from the one registered with the as-
purchased DEX (Figure 1). This difference might be explained by the process of solution and 
crystallization on the laponite surface used in the preparation of the DEX/LAP samples. 
Oriented samples of LAP can be obtained by addition of some drops of a solvent, for 
example acetone. In such case (Figure 1B), the basal spacing of laponite (14.3 Å) is in good 
agreement with the layer thickness (9.3 Å) [21] and the interlayer space (5.0 Å) is compatible 
with the presence of partially hydrated sodium cations (diameter of the fully hydrated cation 
= 7.2 Å [28]) in the interlayer space. However, the treatment of DEX/LAP with acetone 
produces the redistribution of DEX, given its solubility in acetone, as shown by the presence 
of DEX particles even at low content. In that case, a basal spacing of 21.5 Å is observable, 
which can be attributed to the presence of DEX crystallites in the interlayer space. Although 
the presence of intercalated DEX molecules between the clay layers is not directly detected, it 
can be inferred from this result. 
6Figure 1. X-ray diffraction patterns of DEX/LAP. A) Non-oriented samples, B) Samples 
oriented by addition of acetone. Pattern for pure DEX is included. (*) Diffraction lines for 
orthorhombic DEX (JCPDS database). 
The IR spectrum of DEX (Figure 2A) is mostly overlapped by the bands corresponding to the 
laponite structure, mainly the broad and intense band due to Si-O-Si bonds (1300-1000 cm1). 
The presence of the organic molecule in DEX(high)/LAP is detectable in the 3000-2800 cm1 
zone, corresponding to the stretching of aliphatic C-H bonds. Only the zone of C=O and C=C 
stretching (Figure 2B) is nearly free from laponite bands, with the only presence of the 
bending band of adsorbed water at 1640 cm1. The bands at 1704 and 1662 cm1 are assigned 
to the C20 (aliphatic) and C3 (unsaturated) carbonyl groups respectively (see Figure 3 for 
structure and numbering of DEX), whereas the C=C bonds (C1-C2 and C4-C5) appear at 
1618 and 1603 cm1. In order to detect more clearly those bands in DEX(high)/LAP, the 
spectrum of LAP was subtracted from the spectra of the samples (Figure 2B). The same C=O 
and C=C bands, slightly enlarged but at the same positions, are observable in 
DEX(high)/LAP samples. Thus, the possible interactions between DEX and LAP surface are 
hardly detectable by IR. 
7Figure 2. IR spectra of pure DEX, pristine LAP, and two samples of DEX/LAP (high 
content) prepared from ethanol and acetone solutions. A) 4000-500 cm1 range. B) 
Enlargement of the 1800-1500 cm1 zone. The spectrum of LAP has been subtracted to those 
of DEX(high)/LAP. 
8Figure 3. Molecular structure and numbering of dexamethasone (DEX). 
Then the nature of the interaction between DEX and LAP surface was studied by solid state 
NMR, and the spectra were compared with those of DEX in solution with different solvents, 
namely CD2Cl2 in high dilution to ensure the lack of any intermolecular hydrogen bond, 
acetone-d6 and dmso-d6, as hydrogen bond acceptor (HBA) solvents with different basicity, 
and CD3OD as a solvent with both hydrogen bond donor (HBD) and HBA capacity (all the 
spectra in liquid phase can be found in Figures S1-S3 in the Supplementary Material). 
Assignment of the 1H and13C signals was done according to APT and HSQC experiments in 
solution, in good agreement with the results reported in the literature for the 1H-NMR 
spectrum in dmso-d6 [29]. Hydroxyls in positions 11, 17 and 21 of dexamethasone were 
involved in intermolecular hydrogen bonds with the solvent in acetone and dmso, as 
demonstrated by the downfield shift in 1H spectrum, and the shift was higher in dmso (Figure 
S4), according to the higher HBA character of the solvent ( = 0.76 vs 0.48 of acetone [30]). 
The similar chemical shift of CH-OH and CH-OH in both acetone and methanol indicates a 
similar behavior of the hydroxyls of dexamethasone in both solvents, in quite good agreement 
with their more similar  values (0.66 and 0.48). In the case of carbonyl groups, the chemical 
shift of C20 in the 13C spectrum is almost not affected by the solvent, probably by the 
participation of an intramolecular hydrogen bond with OH in position 21. On the contrary, 
carbonyl C3, as well as the conjugated sp2 carbons C5 and C1 suffer a significant downfield 
shift in methanol (Figure S5) [31], according to the decrease in electronic density when 
accepting a hydrogen (deuterium) bond. 
In the case of the solid state 13C CP-MAS NMR spectrum of DEX, the signals were assigned 
(Figure 4) according to the dipolar dephasing (DD) experiment (Figure S6) combined with 
the assignment from the spectra in solution. In Table 1 the chemical shifts of the spectra in 
solid state and in CD3OD solution are compared with that of DEX in acetone-d6. Regarding 
carbonyl groups, the most significant change is observed for C3 and the corresponding 
9conjugated carbons C1 and C5, which are shifted downfield (1.8 to 4.4 ppm), in a similar way 
as it happens in CD3OD (3.0 to 4.1 ppm). The donation of a hydrogen bond from the solvent 
can explain this effect, which is mimicked by an intermolecular hydrogen bond between the 
OH in C17 and the carbonyl C3, as shown in the X-ray structure of DEX monocrystals 
(Figure S7) [32]. However, in the solid state spectrum C2 and C4 are also shifted downfield, 
in contrast with the behavior in methanol solution, which can be attributed to the close 
packing in the solid state and the intermolecular influence of the  cloud. This same effect 
might explain the downfield shift of methyl groups, mainly C19, and the upfield shift of 
methylene ones, mainly C7, although conformational changes from liquid to solid phase 
might also be responsible for this effect. Shifts in the signals within the range of 35-45 ppm 
are also present, but the assignment of the signals is less accurate. 
























Table 1. Comparison of DEX 13C chemical shifts in solution and in solid phase NMR.  
 (ppm)a 
Carbon atom Acetone-d6 Solid state CD3OD DEX/LAP 
20 (C=O) 212.3 211.7 (0.6) 212.7 (+0.4) 212.0 (0.3) 
3 (C=O) 186.0 188.0 (+2.0) 189.0 (+3.0) 188.3 (+2.3) 
5 (C=) 166.9 171.3 (+4.4) 171.0 (+4.1) 169.7 (+2.8) 
1 (HC=) 152.7 154.5 (+1.8) 155.9 (+3.2) 
158.0 (+5.3) 
155.3 (+2.6)b 
2 (HC=) 130.2 132.4 (+2.4) 129.8 (0.4) 
130.8 (+0.6) 
128.4 (1.8)b 
4 (HC=) 125.4 126.3 (+0.9) 125.1 (0.3) 126.1 (+0.7) 
9 (CF) 101.6 102.8 (+1.2) n.o. 102.7 (+1.1) 
17 (C-OH) 91.5 91.7 92.0 (+0.5) 91.7 
11 (CH-OH) 72.5 72.9 (+0.4) 72.9 (+0.4) 71.3 (1.2) 
21 (CH2-OH) 67.9 68.1 (+0.2) 68.1 (+0.2) 68.9 (+1.0) 
10 (C) 
» 49c
50.2 50.2 49.3 
13 (C) 48.3 49.5 49.3 
14 (CH) 44.7 44.5 (0.2) 45.0 (+0.3) 44.4 (0.3) 
12 (CH2) 37.1 40.7 d 37.5 (+0.4) 38.8 (+1.7) 
16 (CH) 36.7 36.7 d 37.1 (+0.4) 36.3 (0.4) 
8 (CH) 35.1 36.7 d 35.6 (+0.5) 32.9 (2.2) 
15 (CH2) 33.1 33.0 33.5 (+0.4) 28.1 (5.0) 
11
6 (CH2) 31.6 31.0 (0.6) 32.2 (+0.6) 27.7 (3.9) 
7 (CH2) 28.4 26.7 (1.7) 28.8 (+0.4) 25.4 (3.0) 
19 (CH3) 23.7 26.7 (+3.0) 23.6 25.4 (+1.7) 
18 (CH3) 17.4 18.1 (+0.7) 17.5 18.6 (+1.2) 
22 (CH3) 15.3 15.9 (+0.6) 15.3 16.7 (+1.4) 
a In parenthesis the difference with respect to the chemical shift in acetone solution (). b
Split signal. c The signal for C10 is a doublet overlapped with the signal for C13. d Tentative 
assignment. 
The signals in the 13C CP-MAS NMR spectrum of DEX(high)/LAP (Figure 5) were also 
assigned according with the DD spectrum (Figure S8). The chemical shifts are gathered in 
Table 1 and it can be seen that they are significantly different from those of pure DEX. A set 
of signals (C15, C6, C7, C8) suffer a significant upfield shift (2.2 to 5.0 ppm) with respect to 
solution NMR that was not observed in the spectrum of pure DEX. On the other hand, 
although the intermolecular DEX-DEX interactions should ideally disappear, the effect on 
C1, C3, C5 remains (downfield shifts 2.3 to 5.3 ppm), as well as on C12 and C19 (1.7 ppm 
downfield shift), whereas the effects on the rest of carbons are of lower magnitude. This 
seems to indicate some polarization of the molecule (Figure S9), that can be explained by an 
interaction of carbonyl C3 and probably OH in C11 with the solid, through either 
coordination to Na ions or hydrogen bonds (hydrated Na ions as HBD and oxygen atoms in 
laponite sheets as HBA), that produces a deshielding of the carbon atoms involved in the 
interactions or in the neighborhood of them, whereas the carbon atoms in the other side of the 
molecule suffer an opposite shielding effect. In some cases (C1 and C2) the signals appear 
split in two, probably because of the existence of several adsorption modes on the surface. It 
is possible that some DEX molecules are directly involved in an interaction with the LAP 
surface, whereas others are supported by means of an intermolecular DEX-DEX interaction, 
in agreement with the presence of small DEX crystallites on LAP, as shown in the XRD 
patterns (Figure 1). 
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Figure 5. 13C CP-MAS NMR spectrum of DEX(high)/LAP. 
3.2. In vitro DEX release from LAP 
Vitreous humor is made up of 99% water with a saline content of about 0.9% [33], thus saline 
solution was chosen as a first approach to a vitreous model. As vitreous volume in rabbit is 
around 1.4-1.7 mL [34], the experiments of DEX delivery were carried out in 2 mL of saline 
solution by suspending 20 mg of solid. In this way the introduced amounts of DEX, 0.95, 
1.82 and 3.33 mg for low, medium and high content DEX/LAP respectively, were by far 
superior to the toxic dose in rabbits (0.4 mg [35]), just to test if the amount present in solution 
reached that limit value. In this case the release mechanism should be the quite fast 
equilibrium between the physisorbed and the dissolved DEX, with further release once the 
DEX in solution is consumed. In a first set of experiments with DEX(high)/LAP and 
DEX(low)/LAP, after equilibration for 24 or 48 h under stirring, the solid was separated by 
ultracentrifugation (14000 rpm, 20 min), the supernatant was analyzed by HPLC and the 
solid was suspended again in a new volume of saline solution to simulate the consumption of 
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dissolved DEX in the vitreous humor in the eye. The average of the amounts release at the 
two equilibration times, with the error bars, is represented in Figure 6. As can be seen, the 
amounts released lead to concentrations below the reported solubility of dexamethasone in 
water (0.08-0.1 mg/mL). This result demonstrates the reproducibility of the in vitro
measurements, as well as the role of laponite in the release control, in spite of the lack of any 
strong electrostatic interaction. This result contrasts with other described methods, using 
microparticles to encapsulate dexamethasone [36], in which DEX is immediately released 
according to its solubility in the extraction medium. Only in the case of the high loading 
sample, the obtained concentration (up to 0.07 mg/mL) is close to the DEX solubility. These 
experiments do not fulfil the sink conditions, that prevent reaching concentrations too close to 
the solubility limit. However, those conditions are used to prevent the effect of the 
concentration to the release rate in kinetic release experiments. In our case, we are dealing 
with thermodynamic experiments, as much close as possible to the real situation, in which it 
would be desirable the presence of a large amount of drug, with a limited amount of liquid 
phase (vitreous humor), to minimize the number of intraocular injections.  
Figure 6. Release of DEX (in mg) from DEX(high)/LAP (circles) and DEX(low)/LAP 
(squares) to saline solution. Each point is the average of the amount released after 24 h and 
48 h equilibration time. 
14
The cumulative DEX release in 10 consecutive saline solutions after 24 h equilibration time 
is represented in Figure 7. As can be seen, the cumulative release was almost linear, 
irrespective from the DEX loading on LAP, with released amounts of 0.131, 0.057 and 0.019 
mg in average per extraction (in 2 mL of saline solution) for high (1:5), medium (1:10) and 
low (1:20) loading levels respectively. These values correspond to released percentages of 
around 38, 28 and 19% of the initial DEX amount after 10 extractions for high (1:5), medium 
(1:10) and low (1:20) loading levels respectively. As can be seen, the percentage released 
also increases when the initial DEX content is higher. This behavior may indicate the 
existence of different interactions: a strong interaction with the clay, dominant in the sample 
with the lowest DEX content, and a weaker interaction, probably between DEX molecules, 
accounting for the higher percentage released in the samples with higher DEX content. This 
result is in agreement with the presence of DEX particles, detected by XRD in 
DEX(high)/LAP (Figure 1). 
Given the role of LAP demonstrated in the first set of results of extractions in saline, it was 
decided to test a liquid medium more similar to the vitreous humor. Taking into account that 
the characteristic viscosity of vitreous is attributed to the presence of hyaluronic acid and 
collagen [37], we tried to mimic its physical properties by using sodium hyaluronate in saline 
solution. As the vitreous viscosity is in the range 300-2000 cP, it is necessary to use a 
concentration of at least 0.5% of sodium hyaluronate in saline solution to reach a viscosity 
that falls into this range [38]. Hence, the solid sample with medium loading (DEX/LAP = 
1:10 w/w) was successively treated with 2 g of solution of hyaluronic acid in saline solution 
(1:5 w/w ratio). After 24 h equilibration time, the laponite was separated by 
ultracentrifugation and the liquid was analyzed by HPLC. The amount released to this new 
liquid medium (Figure 8) was lower than in the case of saline solution, with an average of 
0.036 mg per extraction (vs 0.057 mg in saline) accounting for 1.9% of the initial amount of 
DEX released (vs 3.1% in saline). Moreover, desorption to the model of vitreous humor starts 
to deviate from linearity earlier, confirming the slower release of dexamethasone to this 
medium. Again, this behavior points to the existence of two different interactions. In the first 
extractions, molecules with a weak interaction, probably DEX-DEX interactions instead of 
DEX-LAP ones, are preferably released, whereas the molecules interacting with the surface 
start to desorb from the fifth extraction. Thus the thermodynamic equilibrium between the 
DEX in solution and adsorbed onto LAP depends on several factors, including the loading of 
DEX on the solid and the liquid extraction medium. 
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Figure 7. Cumulative release of DEX from DEX(high)/LAP (), DEX(med)/LAP (¨), and 
DEX(low)/LAP () to saline solution: in mg (A) and percentage of the starting DEX content 
in the solid (B).  
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Figure 8. Cumulative release of DEX from DEX(med)/LAP to saline solution () and the 
model for vitreous humor (¨): in mg (A) and percentage of the starting DEX content in the 
solid (B). 
Given the probable role of hydrogen bonding in the retention mechanism of DEX on LAP, 
the solvent used for DEX deposition (ethanol) could compete with the drug and reduce the 
DEX-LAP interaction. To check this possibility, the adsorption solvent was changed to 
acetone in an attempt to enhance the interaction of DEX with the surface. The same three 
loadings were tested in the release to saline solution and in Figure 9 the results are compared 
with those obtained with the solids prepared in ethanol. 
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As can be seen, the desorbed amount is always lower than in the case of ethanol, with an 
earlier deviation from the linearity, showing that the interaction between dexamethasone and 
the laponite surface is slightly stronger, and the release is slower. However, the CP-MAS 
NMR spectrum of DEX/LAP prepared from acetone solution did not reveal any significant 
difference in chemical shifts. Only slightly broader signals were obtained, a fact that can be 
explained by a lower mobility of the molecules on the solid or by the existence of a larger 
number of different adsorption modes. 
4. Conclusion 
In this work we have demonstrated that non-ionic drugs, such as dexamethasone, can be 
retained on laponite, mainly through hydrogen bonding involving hydroxyl and carbonyl 
groups. The drug is slowly released to saline solutions, as models for vitreous humor, and the 
released amount depends on the loading of the drug in the solid, the composition of the liquid 
phase (saline solution or hyaluronic acid solution) and even the solvent used in the 
preparation of the solid. The transparency of the laponite support and their gels in water, as 
reported in the literature [21, 39] and also checked in our laboratory (Figure S10), makes it 
suitable for biocompatibility tests in intraocular injections. A deep study in rabbits is 
currently being finished, and its positive results prompted us to use this simple methodology 
for in vivo experiments of dexamethasone release that are currently in progress. These results 
also open the door for the use of laponite as a carrier for controlled delivery of other non-
cationic drugs bearing hydrogen bond donor groups, such as hydroxyls or carboxylic acids. 
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Figure 9. Cumulative release of DEX (in mg) to saline solution from DEX/LAP samples 
prepared in ethanol () or acetone (¨): A) DEX(low)/LAP, B) DEX(med)/LAP, C) 
DEX(high)/LAP. 
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